(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 23 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NITST3czPTBxNUCwM|ExODBibl2= Mn3yNlQwPDhxN{KgbC=> NWP5bllbTE2VTx?= NHO3bY9qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NFzlSY8zPjdyN{i4NS=>
BCPAP MnTGR4VtdCCYaXHibYxqfHliQYPzZZk> MWiyOVAwPTByL{GwNFAhdk1? NELxbYEzPC92OD:3NkBp MWXEUXNQ M1:zZ4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NF\pfG8zPjdyN{i4NS=>
K1  MXPD[YxtKEO7Y3zlJGF{e2G7 NES4SZAzPTBxNUCwM|ExODBibl2= NXLoc45lPzJiaB?= M3HDO2ROW09? M120TYFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= NI\sUXIzPjdyN{i4NS=>
BCPAP Mmi2R4VtdCCFeXPs[UBCe3OjeR?= NYDyT3B7OjVyL{WwNE8yODByIH7N MmTEO|IhcA>? M2faXmROW09? M4T3WIFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= MknFNlY4ODd6OEG=
Hep3B NEf2[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInXV3oxNTFyIN88US=> NXTHZ242PSCm NVXV[JpDTE2VTx?= M4flUGlEPTB;MD6wPEDPxE1? NHrKdXYzPjV5NUG2Oy=>
HCCLM3 NX\LO29yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LJOFAuOTBizszN NV3lNnZWPSCm NYPrcWIyTE2VTx?= M4raZWlEPTB;MD6xOEDPxE1? NX2xZWhrOjZ3N{WxOlc>
HuH7 M1nIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmwMVExKM7:TR?= NX\IRY12PSCm Mne0SG1UVw>? MoO0TWM2OD1yLkKxJO69VQ>? NYruO24yOjZ3N{WxOlc>
HepG2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOwMVExKM7:TR?= NGHWfpY2KGR? M3HVSmROW09? M2e0[GlEPTB;MD6zOEDPxE1? MX[yOlU4PTF4Nx?=
SMMC7721 M4PJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2wMVExKM7:TR?= NVrWWYhxPSCm M3W3R2ROW09? MnLFTWM2OD1yLkSxJO69VQ>? NY\OepBKOjZ3N{WxOlc>
BEL7402 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLvbItIOC1zMDFOwG0> NUjqSFZmPSCm NH\iUndFVVOR MmDFTWM2OD1yLkS3JO69VQ>? NH\X[YEzPjV5NUG2Oy=>
MHCC97H MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXyyeJFXOC1zMDFOwG0> M1u5U|Uh\A>? NYXBR3BCTE2VTx?= NWDnXVVmUUN3ME2wMlQyKM7:TR?= NFP1dXgzPjV5NUG2Oy=>
Hep3B NYHaPIsxS2WubDDDfYNt\SCDc4PhfS=> M1;QXVAvOS9yLkWvNk42KM7:TR?= MWG0PEBp NVPSW|U1TE2VTx?= NH;ocFRt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iCKQ1OgZ4VtdHNiaX6gd5VjNUdzIIDoZZNmyqB? NED6VGIzPjV5NUG2Oy=>
HCCLM3 MVHD[YxtKEO7Y3zlJGF{e2G7 MoPONE4yNzBwNT:yMlUh|ryP NGexToY1QCCq NXrzWXVGTE2VTx?= M4H0Soxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? NY\B[Yx7OjZ3N{WxOlc>
Hep3B NEnVZXFCeG:ydH;zbZMhSXO|YYm= MkTPNE4yNzBwNT:yMlUh|ryP MoDEOFghcA>? NIDxb|lFVVOR M1W2bYFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? M33INFI3PTd3MU[3
HCCLM3 Ml;TRZBweHSxc3nzJGF{e2G7 MkC2NE4yNzBwNT:yMlUh|ryP NETGbWo1QCCq NGDqd2lFVVOR MVfhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli NWHHTFJOOjZ3N{WxOlc>
A549 NHzhUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPGeoIxNjFvMUCg{txO M1rlVlczKGh? MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYDhS2pLOjZ2MUWyNlU>
H157 NGmxeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXSy[IJIOC5zLUGwJO69VQ>? MnixO|IhcA>? M1q5NYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYjaZ5BoOjZ2MUWyNlU>
H1299 M1jJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPRZmUxNjFvMUCg{txO NHfmZpE4OiCq MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4S2cFI3PDF3MkK1
A549 NYCwboNSTnWwY4Tpc44hSXO|YYm= NIjjXoQyNzJwNT:1JO69VQ>? M3rDVlEzKGh? M{i5deKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? NXuxeGtROjZ2MUWyNlU>
H1299 MoewSpVv[3Srb36gRZN{[Xl? MkL3NU8zNjVxNTFOwG0> NGnHUIkyOiCq NVXqVIhuyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= MYeyOlQyPTJ{NR?=
H157 M136NWZ2dmO2aX;uJGF{e2G7 NXHrOld[OS9{LkWvOUDPxE1? NU\lSYJ[OTJiaB?= M2TxTYRm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= NHfqUJQzPjRzNUKyOS=>
H1299 MYfGeY5kfGmxbjDBd5NigQ>? M3j2WFEwOi53L{Wg{txO M1vZ[lEzKGh? M2fpRYRm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= NIGwRmozPjRzNUKyOS=>
C8161 NUfveHdYS2WubDDWbYFjcWyrdImgRZN{[Xl? MoXGNE0zKM7:TR?= NHHHb201KGR? MnTqSG1UVw>? MlXK[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Ml7VNlY{QTd{MkO=
Mel285 M3PyfmNmdGxiVnnhZoltcXS7IFHzd4F6 Mn3FNE0zKM7:TR?= NHjob4g1KGR? MX\EUXNQ NUf6WYox\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MX[yOlM6PzJ{Mx?=
Mel290 NITDXJlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVvycplMOC1{IN88US=> MWO0JIQ> MnHOSG1UVw>? M1PqO4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHruN4ozPjN7N{KyNy=>
92.1 NHXOWZlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX\DVVZoOC1{IN88US=> MXK0JIQ> MW\EUXNQ NEDRbopl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3ewb|I3Ozl5MkKz
Omm1.3 NVjES|R3S2WubDDWbYFjcWyrdImgRZN{[Xl? M16zSFAuOiEQvF2= NVvPUFg{PCCm NYDGflFzTE2VTx?= MYnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFz1S3ozPjN7N{KyNy=>
Mel202 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{DTb|AuOiEQvF2= M2nNS|Qh\A>? M2\QVGROW09? MkPC[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYXk[XlnOjZ|OUeyNlM>
Mel270 MmfhR4VtdCCYaXHibYxqfHliQYPzZZk> NG\ud4QxNTJizszN Mn3QOEBl MlXoSG1UVw>? M2\6bYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3zQbVI3Ozl5MkKz
Omm1 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX6wMVIh|ryP NHvSclE1KGR? MojpSG1UVw>? NWCwOFF3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUHqc2VFOjZ|OUeyNlM>
92.1 NF\rRYdCeG:ydH;zbZMhSXO|YYm= NIHpXIE2ODBibl2= MmnXOFghcA>? MV3EUXNQ M{D0UIlv\HWlZYOgZZBweHSxc3nz NFWyRo8zPjN7N{KyNy=>
Omm1.3 NHrueoVCeG:ydH;zbZMhSXO|YYm= Mnv4OVAxKG6P MYG0PEBp NGHBW3VFVVOR MYjpcoR2[2W|IHHwc5B1d3Orcx?= M1PYPVI3Ozl5MkKz
92.1 NF\vcmVE\WyuIFP5Z4xmKEG|c3H5 Mn\GOVAxKG6P NUW1cXAzOjRxNEivO|IhcA>? NWjBdlhLTE2VTx?= MYfpcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? NGL1bmIzPjN7N{KyNy=>
Omm1.3 M3PPUmNmdGxiQ4njcIUhSXO|YYm= MU[1NFAhdk1? M17mXVI1NzR6L{eyJIg> MVXEUXNQ MkG0bY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? MX[yOlM6PzJ{Mx?=
A549 NYj1[5E3TnWwY4Tpc44hSXO|YYm= NX\ZUIVuOTByL{SwNE8yODByIH7N M1;P[|I1KGh? MYr1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy NYDzZ4lpOjZ{MUKxPVk>
MCF-7 NYrOboZUTnWwY4Tpc44hSXO|YYm= NYLLVnlDOTByL{SwNE8yODByIH7N NH7ROlYzPCCq M{i3W5VxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? MnjUNlYzOTJzOUm=
HEK293 M3r0OWZ2dmO2aX;uJGF{e2G7 NIO2TGQyODBxNECwM|ExODBibl2= NYjoOmFyOjRiaB?= NHTzS|h2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz NYDxVmluOjZ{MUKxPVk>
858 MkO1R4VtdCCYaXHibYxqfHliQYPzZZk> M3\JNVAuOSEQvF2= MmTPOUBl M13qe2ROW09? NXO5UW1W\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXvQTmdmOjZ{ME[zN|M>
DDR2L63V NFe3S2pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NULudHN3OC1zIN88US=> M3HEdFUh\A>? NYO1[5N4TE2VTx?= Mn3z[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHX2OWozPjJyNkOzNy=>
BE(2)-C MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFjoeZMyKM7:TR?= NG\jUm4yNTRiZB?= MVPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MWqyOlA3PzR4NB?=
IMR-32 MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUW5SpNPOSEQvF2= MYqxMVQh\A>? NEf6WoRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NX\rNIhxOjZyNke0OlQ>
JF Mmm0R4VtdCCYaXHibYxqfHliQYPzZZk> NY\lUXNMOSEQvF2= Mn;FNU01KGR? Mofj[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MnjoNlYxPjd2NkS=
BE(2)-M17 M1;JfmNmdGxiVnnhZoltcXS7IFHzd4F6 MX:xJO69VQ>? NIK3ZZEyNTRiZB?= NXfWeWk{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M3TacVI3ODZ5NE[0
SK-N-SH MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3vzRVEh|ryP Mn3WNU01KGR? Mnzz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MX:yOlA3PzR4NB?=
SK-N-DZ  MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn:xNUDPxE1? NYfm[21MOS12IHS= MV7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> NHXx[IszPjB4N{S2OC=>
HMC-1.1  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILw[Jc2NTVyMECgcm0> MoDvOFghcA>? NG\jd3lFVVOR NUmxTlhtcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWfoNFdxOjZyNUWzNFM>
HMC-1.2 NUjuZ4dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHXOU02ODByIH7N NVrXV|l3PDhiaB?= MmLqSG1UVw>? MkDHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3jsXFI3ODV3M{Cz
ROSA KIT WT  M3jrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\P[mE2NTVyMECgcm0> NYLPVJl2PDhiaB?= NFTiXVZFVVOR MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUG4[3JuOjZyNUWzNFM>
ROSA KIT D816V MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInpNJM2NTVyMECgcm0> MlS0OFghcA>? MUPEUXNQ NXLZWY91cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF6wTZEzPjB3NUOwNy=>
HMC-1.1  NHH5TpBCeG:ydH;zbZMhSXO|YYm= NXnWdY5kOjByLUWwNFAhdk1? MWC0PEBp NV;ScY9OTE2VTx?= NYiydoxHcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVWyOlA2PTNyMx?=
HMC-1.2 MV\BdI9xfG:|aYOgRZN{[Xl? M1LHOlIxOC13MECwJI5O M33DVVQ5KGh? M3\YV2ROW09? NIjKVmtqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3fme|I3ODV3M{Cz
ROSA KIT WT  MonFRZBweHSxc3nzJGF{e2G7 NXjUNItXOjByLUWwNFAhdk1? NELyN4I1QCCq M3j3cmROW09? NFj1S|lqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmDJNlYxPTV|MEO=
ROSA KIT D816V MXPBdI9xfG:|aYOgRZN{[Xl? MlHmNlAxNTVyMECgcm0> Ml\VOFghcA>? MkKwSG1UVw>? M1m3OIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHToe5AzPjB3NUOwNy=>
494H MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX6c3g4PzJiaB?= NFX2eFRFVVOR MUHJR|UxRTBwMUKyxtExNjByNDFOwG0> M{jFXlI2QTR2NU[2
493H M2DveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H6OVczKGh? M2LKcmROW09? M{fGU2lEPTB;MD6wOFfDuTBwMEC5JO69VQ>? M1\sclI2QTR2NU[2
716H NGXVNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NkBp MU\EUXNQ MUXJR|UxRTBwMkGyxtExNjB|NDFOwG0> MU[yOVk1PDV4Nh?=
148I MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPsO|IhcA>? NHjvR21FVVOR MXHJR|UxRTBwMki0xtExNjB|NTFOwG0> NFj3O4ozPTl2NEW2Oi=>
98Sc M1nlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVe3NkBp M{Cxb2ROW09? M1jjVmlEPTB;MD6xNVXDuTBwMEC0JO69VQ>? M{fxUVI2QTR2NU[2
89R NGLkXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6z[ZpCPzJiaB?= MYHEUXNQ M3r4U2lEPTB;MD6xNlbDuTBwMECzJO69VQ>? M{TDXlI2QTR2NU[2
494L MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjqO|IhcA>? MVPEUXNQ MlXDTWM2OD1yLkOxO:KyOC5yMUKg{txO NHXmbmwzPTl2NEW2Oi=>
493L MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVq3NkBp MnLBSG1UVw>? NFjHNWZKSzVyPUCuNFUxyrFyLkCxNUDPxE1? Mo\GNlU6PDR3Nk[=
148L MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPkO|IhcA>? M2Cyb2ROW09? NEXkUWtKSzVyPUCuNVQ3yrFyLkCxO{DPxE1? MX6yOVk1PDV4Nh?=
98L M1v2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\EbVczKGh? NUPBW29MTE2VTx?= NImy[mVKSzVyPUCuN|A6yrFyLkCyPUDPxE1? NFvvV3MzPTl2NEW2Oi=>
OS17 NXeyVmhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPVbWY4OiCq M2KzfmROW09? NGe0WGFKSzVyPUCuNFc6yrFyLkCwN{DPxE1? MXuyOVk1PDV4Nh?=
OS9 NYDWXWczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS4To84OiCq MXjEUXNQ Mn7MTWM2OD1yLkSwOuKyOC5yMkig{txO MV6yOVk1PDV4Nh?=
MG63 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVu3NkBp MoHhSG1UVw>? M2XqbWlEPTB;MD6xNVTDuTBwMEK1JO69VQ>? M4[1TlI2QTR2NU[2
SAOS2 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC3NkBp M4XHUWROW09? NF;HUpRKSzVyPUCuNlE4yrFyLkCwN{DPxE1? MW[yOVk1PDV4Nh?=
U2OS NUn2SIlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmqxO|IhcA>? MnvPSG1UVw>? MUfJR|UxRTBwMUm4xtExNjByODFOwG0> MV[yOVk1PDV4Nh?=
SJSA-1 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu3NkBp NYWxb4ZoTE2VTx?= MUPJR|UxRTBwMUCwxtExNjBzMDFOwG0> NFTk[ZMzPTl2NEW2Oi=>
494H MVjBdI9xfG:|aYOgRZN{[Xl? MmjaNE4zPS9yLkWvNU4xKM7:TR?= M3nsZlI1KGh? NYTiR2M1TE2VTx?= MYLpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NHHQfW8zPTl2NEW2Oi=>
148I NU[2O40ySXCxcITvd4l{KEG|c3H5 NYjhNII4OC5{NT:wMlUwOS5yIN88US=> NI\sVWozPCCq NW\iTI5LTE2VTx?= MYLpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MWmyOVk1PDV4Nh?=
OS17 M{T0U2Fxd3C2b4Ppd{BCe3OjeR?= M3raRVAvOjVxMD61M|EvOCEQvF2= Mn\HNlQhcA>? M2G3WGROW09? M1rONIlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? MormNlU6PDR3Nk[=
494H NXr6OWFiSXCxcITvd4l{KEG|c3H5 NVPhSXJQOeLCid88US=> Mnr5OFghcA>? MYLEUXNQ NFGwZ|hqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> M3;zU|I2QTR2NU[2
148I MnLURZBweHSxc3nzJGF{e2G7 NUjZVXJYOeLCid88US=> MYS0PEBp M2r5OWROW09? M2f2UYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> MXeyOVk1PDV4Nh?=
OS17 NX\CfYl2SXCxcITvd4l{KEG|c3H5 MkDTNgKBkc7:TR?= MYK0PEBp MmHtSG1UVw>? NHzYeWJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> NWPIRWRwOjV7NES1OlY>
MOLM13 MlHtRZBweHSxc3nzJGF{e2G7 MVmyOVAhdk1? NI\GTGE1QCCq NX\1V|NwTE2VTx?= M4mxdYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= MmXBNlUxPTN6MkW=
MV4-11  NX;t[ZBpSXCxcITvd4l{KEG|c3H5 NGnodlUzPTBibl2= MWe0PEBp M3vqb2ROW09? MXLpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? MUCyOVA2Ozh{NR?=
MOLM13 MoPqSpVv[3Srb36gRZN{[Xl? MkjpNlUxKG6P NWrwfWI6OjRiaB?= M3SzfGROW09? MUflcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? MoLXNlUxPTN6MkW=
MV4-11  M{OzZWZ2dmO2aX;uJGF{e2G7 MnnSNlUxKG6P MYGyOEBp NXzIenduTE2VTx?= NXzIUHdT\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ NX;z[ndJOjVyNUO4NlU>
MOLM13 MVjBdI9xfG:|aYOgRZN{[Xl? NX3kUYduOjVyIH7N M3jhNVQ5KGh? NUK1WWF5TE2VTx?= M3OyUIlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? M2q3UVI2ODV|OEK1
MV4-11  NXrNcJRJSXCxcITvd4l{KEG|c3H5 NWO3WHY5OjVyIH7N MXe0PEBp NInreWdFVVOR M{\vNolv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? MX[yOVA2Ozh{NR?=
Hela MkfCR4VtdCCYaXHibYxqfHliQYPzZZk> Ml;INE02ODBibl2= NVPQXJV5PzJiaB?= M3rie2ROW09? MUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVyyOVAxQTJ7NR?=
HBL-1 NGjMU5JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHjwU|ExNTVyMDDuUS=> NWDaUG1RPzJiaB?= M{fS[WROW09? NY\IRVR{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3zwcVI2ODB7Mkm1
HLY-1 MoHZR4VtdCCYaXHibYxqfHliQYPzZZk> MoLVNE02ODBibl2= M3rO[lczKGh? M{XhSmROW09? MlLR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXfiOFUyOjVyMEmyPVU>
OCI-Ly3 MmHhR4VtdCCYaXHibYxqfHliQYPzZZk> MVewMVUxOCCwTR?= M3u0V|czKGh? NIfZVIRFVVOR M1\XcIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVf2T2dMOjVyMEmyPVU>
OCI-Ly10 NIrIXWFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M37URlAuPTByIH7N MUG3NkBp NVPrW2FsTE2VTx?= M3XtZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NE\aeZgzPTByOUK5OS=>
SU-DHL-4 MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXPhOZVUOC13MECgcm0> MoXJO|IhcA>? NVr4UFhzTE2VTx?= M1S2eIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mny1NlUxODl{OUW=
SU-DHL-5 NX:3S2VPS2WubDDWbYFjcWyrdImgRZN{[Xl? MV2wMVUxOCCwTR?= MYi3NkBp M37VOGROW09? M{DZUYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MojCNlUxODl{OUW=
SU-DHL-6 MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUDTOmVoOC13MECgcm0> NXTXd3dQPzJiaB?= NVHkPGYxTE2VTx?= M2rjRYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2\zZlI2ODB7Mkm1
SU-DHL-10 NUDVeIZjS2WubDDWbYFjcWyrdImgRZN{[Xl? M160blAuPTByIH7N MkjOO|IhcA>? NH3yc|hFVVOR NXjHV|Ux\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NEHZTZIzPTByOUK5OS=>
RC-K8 MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1H6dFAuPTByIH7N NUnGeHZ2PzJiaB?= NWj6SI1LTE2VTx?= Mojk[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXqyOVAxQTJ7NR?=
OCI-Ly8 MoXqR4VtdCCYaXHibYxqfHliQYPzZZk> MljKNE02ODBibl2= MVm3NkBp NIT3N2xFVVOR NHLJRpNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mkm5NlUxODl{OUW=
OCL-Ly18 NXHuN45VS2WubDDWbYFjcWyrdImgRZN{[Xl? MUmwMVUxOCCwTR?= MlPGO|IhcA>? NUXY[GJbTE2VTx?= MkHK[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGe3OmYzPTByOUK5OS=>
OCI-Ly3 M32zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPR[pZQOTd{L{K1NE82ODBibl2= Mkm1Nk84KGR? MV\EUXNQ NI\1WFlqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg Mn7INlUxODl{OUW=
OCI-Ly8 M3PzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\RNVczNzJ3MD:1NFAhdk1? M33hUFIwPyCm M4fJbmROW09? MWDpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi MkH1NlUxODl{OUW=
SU-DHL-4 NWHQb48xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULVXWp{OTd{L{K1NE82ODBibl2= MYOyM|ch\A>? MVLEUXNQ MWrpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi MlziNlUxODl{OUW=
SU-DHL-10 MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG2OIFlOTd{L{K1NE82ODBibl2= NFryXHEzNzdiZB?= NGixOm5FVVOR NXrWNpNQcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> MnKxNlUxODl{OUW=
OCI-Ly3 NFvFPYNCeG:ydH;zbZMhSXO|YYm= M1LGUlE4Oi9{NUCgcm0> NIriXZI4\A>? M17lPGROW09? MYXpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= MXmyOVAxQTJ7NR?=
OCI-Ly8 NIPUTnhCeG:ydH;zbZMhSXO|YYm= MlPsNVczNzJ3MDDuUS=> NIXoO4M4\A>? MlvFSG1UVw>? M{Hkeolv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> NFLTZYszPTByOUK5OS=>
SU-DHL-4 M4Xp[GFxd3C2b4Ppd{BCe3OjeR?= MWKxO|IwOjVyIH7N MmjTO4Q> NXn6TWMxTE2VTx?= MoG2bY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MmWyNlUxODl{OUW=
SU-DHL-10 M1i0OmFxd3C2b4Ppd{BCe3OjeR?= M{XF[lE4Oi9{NUCgcm0> M3zTW|dl NVyx[W85TE2VTx?= MWXpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NVvLR|lvOjVyMEmyPVU>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID